S2Medical

S2Medical S2Medical AB is a wound healing company listed on Nasdaq First North Growth Market in Stockholm.

🚀 Epiprotect Sales Set to Triple in 2024!We’re excited to share that Epiprotect, developed by S2Medical and powered by o...
19/11/2024

🚀 Epiprotect Sales Set to Triple in 2024!

We’re excited to share that Epiprotect, developed by S2Medical and powered by our strategic partner, is projected to achieve triple sales growth in 2024, with secured revenue already exceeding SEK 9 million!

Starting in 2024, our royalty model— 2% of sales revenue and 10% of net profit —provides a stable foundation for long-term growth in the multi-billion-dollar wound care market.

This success accelerates the commercialisation of our other innovative solutions:
AMP technologies – antimicrobial peptides
IvaQ – advanced negative pressure wound therapy
Instagraft – efficient skin grafting

Through our partner’s global network, we’re expanding into new markets and strengthening our leadership in wound care. Stay tuned for more updates as we continue to transform healthcare!

For more information, visit our website:
www.s2m.se

Big News!! 🚀We’re thrilled to announce that the U.S. Patent and Trademark Office has granted us a patent for our groundb...
04/10/2024

Big News!! 🚀

We’re thrilled to announce that the U.S. Patent and Trademark Office has granted us a patent for our groundbreaking technology, Plantaricin NC8 Alpha Beta.
This innovative technology is part of our Antimicrobial Peptide (AMP) platform and has the potential to boost the effectiveness of antibiotics significantly. 💊✨

By enhancing antibiotic efficacy, especially against resistant bacteria like Staphylococcus, this solution could pave the way for more effective treatments of difficult infections and lower the risk of antibiotic resistance — a pressing global challenge.

Our preclinical studies have shown promising results, with strong synergistic effects when combined with antibiotics like vancomycin and gentamicin, offering a new approach to infection treatment, particularly for infections related to medical implants.

This is a major milestone for S2Medical as we continue our mission to improve healing processes and patient outcomes. With this patent, we are positioned for future growth and innovation in the world’s largest medical technology market — the USA. 🇺🇸

A huge thank you to our incredible team and partners for making this possible. Together, we are taking one step closer to transforming infection treatment and addressing one of the greatest medical challenges of our time. 🙌

For more information, visit our website:
www.s2m.se

We have initiated the commercialization of a new cosmetic formulation based on research into antimicrobial peptides (AMP...
13/09/2024

We have initiated the commercialization of a new cosmetic formulation based on research into antimicrobial peptides (AMP) and skin health. We are also applying for INCI listing, expected to take around six months, and plans to develop and launch skincare products shortly after.

In collaboration with Eyracure AB, S2Medical will focus on product development, manufacturing, and commercialization.
This partnership aims to capitalize on both companies' strengths to bring innovative skincare solutions to the market quickly.

With the global cosmetics market valued at USD 300-500 billion, we see great potential to establish ourselves with scientifically-backed products.

This initiative aligns with the company's growth strategy, which is supported by its ongoing rights issue and the acquisition of Eyracure AB.

For more information, visit our website:

S2Medical AB (publ) Rights Issue Update!We are pleased to announce that the subscription period for our previously commu...
03/09/2024

S2Medical AB (publ) Rights Issue Update!

We are pleased to announce that the subscription period for our previously communicated rights issue has officially begun and will run from September 3 to September 17, 2024.

During this period, shareholders with preferential rights can subscribe for new A and B series shares at a subscription price of SEK 0.02 per share.

For every share held on the record date, September 2, 2024, shareholders will receive one subscription right, allowing them to subscribe for two new shares of the same series. In total, up to 576,247,926 shares will be issued, potentially raising approximately SEK 11.5 million before issue costs.

An information memorandum detailing the terms of the rights issue, along with insights into our operations and future plans, is now available on our website. We encourage all shareholders and interested parties to review this document to better understand this investment opportunity and our strategic direction.

For more details, please visit our website:
www.s2m.se

We are pleased to share that the South African patent authorities have granted a patent for BioLAP-20, an innovative mol...
28/08/2024

We are pleased to share that the South African patent authorities have granted a patent for BioLAP-20, an innovative molecule developed by Eyracure AB, a company in which S2Medical is a part-owner.
BioLAP-20 is designed to repair hair by permanently linking damages when activated by specific light wavelengths, marking a significant advancement in hair care.

This patent secures Eyracure’s intellectual property in South Africa, a rapidly growing market for premium cosmetics. In partnership with Lyko, Scandinavia's leading beauty distributor, we are well-positioned to bring BioLAP-20 to market and drive growth in both existing and new markets.

For more information, visit our website:
www.s2m.se

23/08/2024

📊 Interim Report April–June 2024 Summary

We're excited to share some great news from our latest interim report:
Net Sales: Increased to SEK 2.9 million (up from SEK 2.7 million), driven by our successful collaboration with Abena.

Cost Efficiency: We significantly reduced operating expenses, thanks to efficiencies in personnel and other external costs.

Q2 Results: Our efforts paid off, with a strong result of SEK 6.9 million (compared to SEK -5.1 million last year), further boosted by the sale of our Epiprotect technology.

Our team's dedication to innovation and efficiency continues to deliver impressive results. We are looking forward to building on this momentum!

For more information, visit our website:
www.s2m.se

13/08/2024

🌞 We hope everyone is enjoying a well-deserved summer break! Whether you're relaxing on a beach, exploring new places, or simply taking time to recharge, we have some exciting news to share from S2Medical AB!

Today marks a significant milestone for us as we have officially acquired 447 shares in Eyracure AB, bringing our total ownership to 22.3%. This strategic move, approved at our AGM on 7 June 2024, aligns perfectly with our vision to enhance our position in both the medical and cosmetic sectors.

By diversifying our product portfolio and leveraging the innovative technology of Eyracure AB, we are poised to create even greater value for our stakeholders. We look forward to exploring the new opportunities this partnership will bring.

Enjoy the rest of your holidays, and stay tuned for more updates!

For more information, visit our website:
www.s2m.se

Exciting News from S2Medical! 🥳🥳We're thrilled to announce that an independent study published in the *Journal of Plasti...
20/06/2024

Exciting News from S2Medical! 🥳🥳

We're thrilled to announce that an independent study published in the *Journal of Plastic, Reconstructive & Aesthetic Surgery* has shown outstanding results for our product, Epiprotect®. Conducted at Stoke Mandeville Hospital, the study involved 99 pediatric patients (ages 0-18) treated for partial-thickness burns.

Key Findings:
- Epiprotect® provides significant pain relief, safety, and quick and easy follow-ups.
- It demonstrates comparable acute healing outcomes to Biobrane® from Smith & Nephew.
- Most notably, Epiprotect® has a significantly lower infection rate (2.6%) compared to Biobrane® (16.4%).

Our CEO, Petter Sivlér, emphasizes, "The reduction in infection risks with Epiprotect® is an enormously important finding, especially since infections in children can mean the difference between life and death."

We expect these results will accelerate the commercialization of Epiprotect®, leading to increased royalty revenues and further opportunities for expansion.

Stay tuned for more updates as we continue to make strides in pediatric burn healing!

For more information, visit our website:

30/05/2024

We are thrilled to announce that S2Medical AB (publ) is now debt-free after successfully settling all our obligations to creditors.
This milestone marks a significant step forward, confirming the successful implementation of our corporate restructuring measures.

"This achievement is a testament to our resilience and ability to overcome challenges. We've laid a solid foundation for a stable and sustainable future by fulfilling our obligations.
We thank our shareholders and creditors for their unwavering support and trust throughout this process.
We're excited about a bright future where we can focus on increasing sales and continuing to develop and expand our innovative product portfolio.
Special thanks to ABENA, our global partner in healing chronic wounds and burns," says Petter Sivlér, CEO of S2Medical AB (publ).

Onwards and upwards! 🚀

For more information, visit our website:
www.s2m.se

17/05/2024

We're thrilled to share our Q1 2024 interim report highlights!

✅ Net Sales Surge: Achieved SEK 4.1M, up from SEK 0.7M last year, thanks to our collaboration with Abena.

✅ Cost Efficiency: Significant reductions in both personnel and external costs.

✅ Positive Financial Results: Q1 profit of SEK 0.8M compared to a loss of SEK 4.8M in the same period last year.

Key Developments:
Partnership with ABENA to commercialize Epiprotect technology.
Market approval for Epiprotect series in Malaysia.
Successful NUPCO procurement in Saudi Arabia.
Exclusive distribution agreements for Georgian and Filipino markets.
Strategic wins in the Stockholm region's wound care procurement.

Looking Ahead:
Reconstruction plan approved and concluded by the District Court in Linköping.
Annual report to serve as a control balance sheet.

🔗 For the full report, visit: www.s2m.se

We're committed to advancing wound care technology and improving patient outcomes globally. Stay tuned for more updates!

09/05/2024

We're excited to announce that S2Medical AB (publ) has just released its annual report for 2023!

You can now access it on our website: www.s2m.se

Printed copies will also be available at our upcoming annual general meeting on June 7, 2024.

Shareholders and interested parties can request a printed copy by emailing hello@s2m.se.

Stay updated with our latest financial updates and milestones!

22/03/2024

News news news!

We are thrilled to announce that S2Medical has secured positions in the tender for wound care products in Region Stockholm. This achievement underscores our commitment to delivering top-notch healthcare solutions and improving patient outcomes.

Our range of wound care products, including InstaQurett for wound cleansing and Ynolens for odour control, will now be available to enhance patient care in Region Stockholm from September 1, 2024. We're proud to partner with AHC Medical AB, the non-exclusive distributor, in this endeavour.

In addition to this milestone, we are pleased to share that S2Medical AB (publ) has successfully navigated its reconstruction plan, paving the way for a stable and prosperous future. We extend our gratitude to our shareholders and creditors for their unwavering support throughout this journey.

This marks a new beginning for S2Medical, and we are excited to embark on this journey towards greater heights together. Stay tuned for more updates as we continue to strive for excellence in healthcare.

For more information, visit our website:
www.s2m.se

Adress

Sunnorpsgatan 5
Linköping
58273

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när S2Medical postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till S2Medical:

Genvägar

Dela

Typ